Phase I/II Trial of Ipilimumab (Immunotherapy) and Hypofractionated Stereotatic Radiation Therapy in Patients with Advanced Solid Malignancies
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 23 May 2018
At a glance
- Drugs Ipilimumab (Primary)
- Indications Adrenal cancer; Liver cancer; Lung cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 11 May 2018 Status changed from recruiting to active, no longer recruiting.
- 20 Jun 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.